ACR TI-RADS — Thyroid Imaging Reporting & Data System
American College of Radiology TI-RADS (2017) for risk-stratifying thyroid nodules on ultrasound: points from 5 feature categories (echogenic foci are additive) → TR1–TR5 with FNA and follow-up size thresholds.
Score interpretation
→ No FNA. No follow-up beyond standard care.
→ ACR TI-RADS: apart from TR1 (0 points) every nodule scores at least 2 — e.g. a mixed cystic and solid nodule also scores the echogenicity of its solid part. Recheck composition and echogenicity.
→ No FNA. No follow-up.
→ FNA if ≥2.5 cm. Follow with US if ≥1.5 cm at 1, 3, 5 years.
→ FNA if ≥1.5 cm. Follow with US if ≥1 cm at 1, 2, 3, 5 years.
→ FNA if ≥1 cm. Follow with US if ≥0.5 cm annually for 5 years. Consider thyroid MDT.
Interpretation bands for the TI-RADS. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Levothyroxine · Thyroid Hormone
- Liothyronine Sodium (T3) · Thyroid Hormone (T3)
- Potassium Iodide / Lugol's Solution · Thyroid Blocking Agent / Pre-operative Thyroid Preparation
- Liothyronine sodium (T3) · Thyroid hormone (T3)
- Levothyroxine sodium · Thyroid hormone (T4)
- Levothyroxine (Elderly) · Thyroid Hormone
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.